^Kakui N, Tanaka J, Tabata Y, Asai K, Masuda N, Miyara T, Nakatani Y, Ohsawa F, Nishikawa N, Sugai M, Suzuki M, Aoki K, Kitaguchi H (May 2006). "Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor". The Journal of Pharmacology and Experimental Therapeutics. 317 (2): 562–70. doi:10.1124/jpet.105.099705. PMID16436501. S2CID6064389.
^Walker MW, Wolinsky TD, Jubian V, Chandrasena G, Zhong H, Huang X, Miller S, Hegde LG, Marsteller DA, Marzabadi MR, Papp M, Overstreet DH, Gerald CP, Craig DA (Mar 2009). "The novel neuropeptide Y Y5 receptor antagonist Lu AA33810 [N-[[trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl]methyl]-methanesulfonamide] exerts anxiolytic- and antidepressant-like effects in rat models of stress sensitivity". The Journal of Pharmacology and Experimental Therapeutics. 328 (3): 900–11. doi:10.1124/jpet.108.144634. PMID19098165. S2CID20295744.
^Islam I, Dhanoa D, Finn J, Du P, Walker MW, Salon JA, Zhang J, Gluchowski C (Jul 2002). "Discovery of potent and selective small molecule NPY Y5 receptor antagonists". Bioorganic & Medicinal Chemistry Letters. 12 (13): 1767–9. doi:10.1016/S0960-894X(02)00287-1. PMID12067557.
Parker E, Van Heek M, Stamford A (Apr 2002). "Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status". European Journal of Pharmacology. 440 (2–3): 173–87. doi:10.1016/S0014-2999(02)01427-9. PMID12007534.
Berglund MM, Schober DA, Statnick MA, McDonald PH, Gehlert DR (Jul 2003). "The use of bioluminescence resonance energy transfer 2 to study neuropeptide Y receptor agonist-induced beta-arrestin 2 interaction". The Journal of Pharmacology and Experimental Therapeutics. 306 (1): 147–56. doi:10.1124/jpet.103.051227. PMID12665544. S2CID40163065.
Beauverger P, Rodriguez M, Nicolas JP, Audinot V, Lamamy V, Dromaint S, Nagel N, Macia C, Léopold O, Galizzi JP, Caignard DH, Aldana I, Monge A, Chomarat P, Boutin JA (Apr 2005). "Functional characterization of human neuropeptide Y receptor subtype five specific antagonists using a luciferase reporter gene assay". Cellular Signalling. 17 (4): 489–96. doi:10.1016/j.cellsig.2004.09.006. PMID15601626.
Movafagh S, Hobson JP, Spiegel S, Kleinman HK, Zukowska Z (Sep 2006). "Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors". FASEB Journal. 20 (11): 1924–6. doi:10.1096/fj.05-4770fje. PMID16891622. S2CID5566843.
Coletta DK, Schneider J, Stern MP, Blangero J, DeFronzo RA, Duggirala R, Jenkinson CP (Apr 2007). "Association of neuropeptide Y receptor Y5 polymorphisms with dyslipidemia in Mexican Americans". Obesity. 15 (4): 809–15. doi:10.1038/oby.2007.610. PMID17426313. S2CID21069742.